Abstract
The development of new drugs involves an extensive pre-clinical characterization and safety documentation followed by a time-consuming search for appropriate clinical dose levels. Drug development is a time-consuming and costly procedure: The molecule-todrug-time is about 15 years, whereas an investment of about 500 million to 1 billion euro is required to reach registration of a new drug (Campbell 1995; Halldin et al. 2001 a) (Fig. 1). The advent of positron emission tomography (PET) with allied techniques has resulted in a revolutionary change in this respect, as the application of PET in drug development and testing can significantly reduce both molecule-to-drug time and costs (Maziere et al. 1991; Maziere and Delforge 1994; Campbell 1995; Halldin et al. 1995, 2001 a; Farde 1996; Burns et al. 1999; Fowler et al. 1999; Gibson et al. 2000; Eckelman 2002).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
